Johnson & Johnson has abandoned development of anti-RSV drug AL-8176, wiping another $900 million off the value of the assets it acquired from Alios Biopharma. The writedown comes months after J&J ...

SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 7, 2014) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has ...

Johnson & Johnson said Tuesday it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company in South San Francisco that is working on treatments for viral diseases. Alios is ...

Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C ...

SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 30, 2014) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement ...

Lawrence Blatt considers himself a born and made entrepreneur — it’s in his DNA, but he also met wonderful mentors along the way who taught him the keys to becoming a successful entrepreneur. It’s ...

SOUTH SAN FRANCISCO, CA– May 30, 2013 – Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory ...

Alibaba has bought a stake in a Chinese microprocessor manufacturer to promote development of of processors which support Alibaba’s operating system – AliOS. AliOS has two flavours – called AliOS ...

Aim is to combine ALS-2200 and ALS-2158 with approved Incivek and investigational candidate VX-222. Vertex Pharmaceuticals is paying Alios BioPharma $60 million up front for worldwide rights to two of ...